Hematologic Cancers News

HEMATOLOGIC CANCER ADVISOR

Hematologic Cancers News

Pepaxto Withdrawn from US Market Following OCEAN Trial Results

The phase 3 OCEAN study evaluated Pepaxto in combination with low-dose dexamethasone in adults with relapsed or refractory multiple myeloma following 2 to 4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy.
Next post in Chronic Lymphocytic Leukemia